Gilead’s Shift: From Antivirals to a Long-Duration Biotech Platform
Gilead is morphing from a steady antiviral cash engine into a diversified biotech platform focused on long-duration oncology and protein-degradation partnerships. With a market cap near $165B, $10.2B in free cash flow and a 2.36% dividend yield, the stock offers a risk-reward where selective long exposure captures upside from pipeline licensing, da…